Page 4 - Xiaobin Wu News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma July 9, 2021 GMT BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 9, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China Nati...

Published: May 07, 2021 May 7, 2021 04:00 UTC Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China This marks the first approval of pamiparib and the third BeiGene-discovered medicine to receive regulatory approval BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib ...

The new facility. Pic:BeiGene BeiGene has announced approval from the China National Medical Products Administration (NMPA) to begin manufacturing its anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China. Production will start immediately at the site, which covers more than one million square feet (100,000 square meters) and boasts 8,000 liters of biologics capacity. An additional phase of construction is set to bring total capacity up to ...

Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE#BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab,...

Press release content from Business Wire. The AP news staff was not involved in its creation. EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China January 25, 2021 GMT HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 25, 2021-- EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT ® (siltuximab fo...

®, including anaphylaxis that has been reported with use of XGEVA ®. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue XGEVA ® therapy permanently. Patients receiving XGEVA ® (denosumab). Osteonecrosis of the jaw (ONJ) has been reported in patients receiving XGEVA ®, manifesting as jaw pain, osteomyelitis, ostei...

®, including anaphylaxis that has been reported with use of XGEVA ®. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue XGEVA ® therapy permanently. Patients receiving XGEVA ® (denosumab). Osteonecrosis of the jaw (ONJ) has been reported in patients receiving XGEVA ®, manifesting as jaw pain, osteomyelitis, ostei...